Oral L-citrulline for fragile preterm babies with lung or bowel disease
Treatments studied
Part of Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This trial studies whether an oral medicine called L-citrulline (L-cit) is safe and how it works in very preterm infants. It includes two groups: babies with chronic lung disease (with or without high blood pressure in the lungs) and babies recovering from severe bowel infection (NEC).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Born at or before 30 weeks of pregnancy (very preterm)
- Be at least 32 weeks after birth (post-menstrual age) for the lung-disease group
- If in the lung-disease group: be on breathing support with certain levels of help for most of the day
- If in the NEC group: have had surgery for Stage IIIb NEC and be tolerating full-ish tube feeds (about 50 mL per kg per day)
- Not have major heart or lung vein narrowing problems (small common holes may be allowed)
- Not currently have serious unstable infection (sepsis) or be expected to die within 7 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether umbilical cord stem cells can help premature babies with severe bronchopulmonary dysplasia (a chronic lung disease) who still need a breathing tube after standard hormone treatment. The goal is to see if it is safe and improves their lung condition.
This trial tests if L-citrulline, a natural substance, can help young children (1 month to 5 years) who are hospitalized with fever and are at moderate to high risk for severe illness. It aims to improve their recovery and reduce complications.
This trial tests whether giving L-carnitine, a nutrient that helps cells make energy, to premature newborns with respiratory distress syndrome (RDS) can improve their health. It may help their bodies cope better in the NICU.
This trial tests whether adding L-citrulline to tube feeding (enteral nutrition) can improve outcomes for people in the ICU with sepsis or septic shock. It may help support the body’s immune response while you’re critically ill.
This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.